Business & Economy

Why a U.K. pharma giant is paying a 40% premium to pivot back to oncology

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition…

Source MarketWatch Updated June 9, 2026 AI Summary

AI Summary

U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.

Read full article on Marketwatch

AI summaries can be wrong sometimes—always verify important details using the source article.

SUPPORT HAPPENINGNOW · Independent AI News Intelligence

SUPPORTER MESSAGE

Enjoyed this article? Consider supporting HappeningNow to help keep independent AI-powered news analysis moving forward. Your contribution helps cover infrastructure, AI summaries, and continued platform development.

Support HappeningNow